European Journal of Clinical Pharmacology (2018) 74:1363 https://doi.org/10.1007/s00228-018-2491-8 LETTER TO THE EDITOR Non-specific treatment effects and the patient perception of costly drug therapy N. W. Boone Received: 18 May 2018 / Accepted: 22 May 2018 / Published online: 31 May 2018 Springer-Verlag GmbH Germany, part of Springer Nature 2018 In our real-world infliximab transition study among consented come uncertain. After all, the product changes that were made immune-mediated inflammatory disease patients, we corrob- to the originator drug during the patent period did not concern orated a nocebo-effect rate of 13% . any physician or patient . Regarding these results, one can conclude that we did ob- serve a relatively high rate of non-specific treatment effects for costly, Bstate-of-the-art^ drug therapy. This presupposes that References physicians and other healthcare providers have influence on the extent to which patients experience the effect of their med- 1. Boone NW, Liu L, Romberg-camps MJ et al (2018) The nocebo icines. Therefore, the confidence of physicians with effect challenges the nonmedical infliximab switch in practice. Eur biosimilars and the biosimilarity concept is key, which is also J Clin Pharmacol 74(5):655–661 underscored in the study of van Overbeeke et al. . 2. van Overbeeke E, de Beleyr B, de Hoon J, Westhovens R, Huys I (2017) Perception of originator biologics and biosimilars: a survey Given the high degree of uncertainty about the effective- among Belgian rheumatoid arthritis patients and rheumatologists. ness and safety of biosimilars, even in bio-naïve patients, as BioDrugs 31(5):447–459 reported by Pineles and colleagues, it seems that the more 3. Schiestl M, Stangler T (2011) Acceptable changes in quality emphasis is placed on the alleged risk differences between attributes of glycosylated biopharmaceuticals. Nat Biotechnol the originator drug and its biosimilar, the more patients be- 29:310–312 * N. W. Boone firstname.lastname@example.org Department of Clinical Pharmacy and Toxicology, Zuyderland Medical Centre, PO Box 5500, 6130 MB Sittard-Geleen, The Netherlands
European Journal of Clinical Pharmacology – Springer Journals
Published: May 31, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera